UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
JANUARY 8, 2019
Date of Report (Date of earliest event reported)
MESA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
|
COLORADO |
0-11740 (Commission File Number) |
84-0872291 |
|
12100 WEST SIXTH AVENUE, LAKEWOOD, COLORADO |
|
80228 |
Registrant’s telephone number, including area code: (303) 987-8000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|_| |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|_| |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|_| |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|_| |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 8.01 OTHER EVENTS
On January 8, 2019 Mesa Laboratories, Inc. announced that H. Stuart Campbell, Mesa’s Lead Independent Director has died at the age of 89.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
|
(d) |
Exhibits: |
| 99.1 | Press release dated January 8, 2019. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
DATE: January 8, 2019 |
Mesa Laboratories, Inc. (Registrant) |
|
| /s/ Gary M. Owens | ||
| BY: | Gary M. Owens, | |
| President and Chief Executive Officer |
Exhibit 99.1
MESA’S BOARD ANNOUNCES DEATH of BOARD MEMBER H. STUART CAMPBELL
Lakewood, Colorado, January 8, 2019 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that H. Stuart Campbell, Mesa’s Lead Independent Director has died at the age of 89. “It is with great sadness and regret that we report the passing of H. Stuart Campbell, Mesa’s longest tenured Director, on December 28, 2018,” said John Sullivan, Chairman of the Board. “Mr. Campbell joined Mesa’s Board in 1983 and was instrumental in guiding Mesa’s development and growth during his 35 years on our Board. Mr. Campbell held several positions at various times, including Chairman of the Board, and most recently as Mesa’s Chair of the Nominating and Governance committee and Lead Independent Director. Mr. Campbell’s quick wit, boundless energy, and business acumen will be sorely missed by the entire Mesa family.”
Mesa will look to fill the vacant director position that this creates as soon as possible, and name both a new Chair of the Nominating and Governance committee and a Lead Independent Director.
About Mesa Laboratories, Inc.
Mesa is a global technology innovator committed to solving some of the most critical quality control and analytical challenges in the pharmaceutical, healthcare, industrial safety, environmental and food & beverage industries. Mesa offers products and services through four divisions (Sterilization and Disinfection Control, Instruments, Cold Chain Monitoring and Cold Chain Packaging) which help its customers ensure product integrity, increase patient and worker safety, and design innovative solutions that improve the quality of life throughout the world.
Forward Looking Statements
This press release may contain information that constitutes "forward-looking statements." Generally, the words "believe," “intend,” “estimate,” "expect," "project," “anticipate,” "will" and similar expressions identify forward-looking statements, which generally are not historical in nature. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future — including statements relating to revenues growth and statements expressing general views about future operating results — are forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our historical experience and present expectations or projections. These risks and uncertainties include, but are not limited to, those described in our Annual Report on Form 10-K for the year ended March 31, 2018, and those described from time to time in our subsequent reports filed with the Securities and Exchange Commission.
CONTACT: Gary Owens.; President and CEO, or John Sakys; CFO, both of Mesa Laboratories, Inc., +1-303-987-8000
For more information about the Company, please visit its website at www.mesalabs.com